Get the Stockscreener App
89.15
0.59%
0.5246
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $89.15, with a volume of 1.07M.
It is up +0.59% in the last 24 hours and up +3.31% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$88.63
Open:
$89.065
24h Volume:
1.07M
Relative Volume:
0.18
Market Cap:
$110.48B
Revenue:
$28.30B
Net Income/Loss:
$126.00M
P/E Ratio:
20.50
EPS:
4.35
Net Cash Flow:
$9.43B
1W Performance:
-3.21%
1M Performance:
+3.31%
6M Performance:
+32.49%
1Y Performance:
+19.36%
1-Day Range:
$88.07
$89.33
1-Week Range:
$86.08
$91.99
52-Week Range:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GILD | 89.15 | 110.48B | 28.30B | 126.00M | 9.43B | 4.35 |
| LLY | 744.39 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.23 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.61 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 170.78 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 98.71 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Intech Investment Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
PNC Financial Services Group Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Natixis Advisors LLC - MarketBeat
Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Legal Desire News Network
Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus.com
Gilead Sciences Issues $3.5 Billion in Senior Notes - Investing.com India
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer - CSRwire.com
How Gilead Is Driving Global Health Equity And Innovation - Forbes
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by First Horizon Advisors Inc. - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Ontario Teachers Pension Plan Board - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Takes $9.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Prospera Financial Services Inc Has $6.59 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead discloses GS-441524 prodrugs for treatment of viral infections - BioWorld Online
Ideaya hires Gilead leader to head up commercialization push - FiercePharma
Parnassus Investments LLC Sells 280,937 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Meeder Asset Management Inc. Purchases 42,444 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Belmont Capital LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead announces impending layoffs, facility closure - LabPulse
26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma
Gilead’s Livdelzi shows promise in PBC clinical trial - Yahoo Finance
Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India
5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat
Gilead Science to Report Q3 Earnings: What's in the Cards? - MSN
Empowering women, eliminating viral hepatitis: Gilead’s vision to help drive public health solutions - STAT
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - BioSpace
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat
CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times
Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com
Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE
Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance
Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - StreetInsider.com
Empowered Funds LLC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
As an HIV+ activist, I know drug companies aren't doing enough to end AIDS - Yahoo News UK
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Option Exercise |
57.92 |
25,000 |
1,448,000 |
125,189 |
| Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Sale |
91.50 |
25,590 |
2,341,485 |
99,599 |
0.70%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):